Two tumors, one target: preliminary experience with 90Y-FAPI therapy in a patient with metastasized breast and colorectal cancer
We report a patient with breast cancer (BC) diagnosed in 2009 with metachronous lymph node, liver, and bone metastases. In 2017, colorectal cancer with peritoneal metastases was additionally diagnosed and treated with 8 cycles of capecitabine due to its antitumor activity against both malignancies....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 2021
|
| In: |
Clinical nuclear medicine
Year: 2021, Volume: 46, Issue: 10, Pages: 842-844 |
| ISSN: | 1536-0229 |
| DOI: | 10.1097/RLU.0000000000003842 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/RLU.0000000000003842 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/nuclearmed/Abstract/2021/10000/Two_Tumors,_One_Target__Preliminary_Experience.13.aspx |
| Author Notes: | Rathke, Hendrik MD; Fuxius, Stefan MD; Giesel, Frederik L. MD, PhD; Lindner, Thomas PhD; Debus, Jürgen MD, PhD; Haberkorn, Uwe MD, PhD; Kratochwil, Clemens MD |
| Summary: | We report a patient with breast cancer (BC) diagnosed in 2009 with metachronous lymph node, liver, and bone metastases. In 2017, colorectal cancer with peritoneal metastases was additionally diagnosed and treated with 8 cycles of capecitabine due to its antitumor activity against both malignancies. At progression of both diseases, FAPI PET/CT demonstrated positive tumor targeting in BC-related metastases and colorectal cancer-related metastases. The patient received an experimental therapy with 90Y-FAPI46. Although there was similar tracer uptake in the PET/CT, the radioligand therapy resulted in mixed response with disappearance of peritoneal metastases but minor efficacy treating the BC-related metastases. |
|---|---|
| Item Description: | Im Titel ist "90" hochgestellt Gesehen am 04.11.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1536-0229 |
| DOI: | 10.1097/RLU.0000000000003842 |